Table 3.
Uni- and multivariable Cox regression analyses to detect association of variables to overall survival (OS).
| Univariable Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | ||
| Extrahepatic disease at first diagnosis of CRLM |
No Yes |
Reference 1.477 (1.029–2.121) |
0.035 | Reference 1.512 (1.011–2.260) |
0.044 |
| Patient-related characteristics | |||||
| Gender | Male | Reference | 0.221 | ||
| Female | 0.861 (0.677–1.095) | ||||
| Age | |||||
| ASA physical status | 1 | Reference | <0.001 | Reference | <0.001 |
| 2 | 0.920 (0.559–1.513) | 1.058 (0.601–1.864) | |||
| 3 | 1.498 (0.884–2.539) | 1.649 (0.907–3.000) | |||
| 4 | 9.958 (1.278–77.610) | 18.836 (2.372–149.565) | |||
| Comorbidities | None | Reference | 0.821 | ||
| Minimal | 1.015 (0.707–1.457) | ||||
| Major | 0.801 (0.396–1.621) | ||||
| BMI | 1.001 (0.974–1.029) | 0.916 | |||
| Disease-related characteristics | |||||
| Primary tumor location | Rectum | Reference | 0.021 | Reference | 0.068 |
| Right-sided colon | 0.793 (0.612–1.029) | 0.862 (0.642–1.157) | |||
| Left-sided colon | 1.187 (0.883–1.595) | 1.276 (0.909–1.791) | |||
| Diagnosis of CRLM | Synchronous a | Reference | <0.001 | Reference | <0.001 |
| Early metachronous b | 1.711 (1.294–2.264) | 1.752 (1.307–2.351) | |||
| Late metachronous c | 1.015 (0.765–1.349) | 0.908 (0.666–1.239) | |||
| Treatment-related characteristics | |||||
| Type of local treatment | Resection | Reference | <0.001 | Reference | 0.056 |
| TA | 1.166 (0.868–1.567) | 1.272 (0.924–1.751) | |||
| Resection and TA | 1.061 (0.789–1.427) | 1.035 (0.748–1.432) | |||
| IRE | 1.466 (0.803–2.675) | 1.560 (0.847–2.873) | |||
| SABR | 2.597 (1.758–3.837) | 2.307 (1.215–4.383) | |||
Categorical variables are reported as number of patients (%); continuous variables are reported as mean (SD). RAS = rat sarcoma viral oncogene homolog; BRAF = V-raf murine sarcoma viral oncogene homolog B; wt = wildtype; mut = mutation; MSS = microsatellite stability; MSI = microsatellite instability; a = synchronous—within 8 weeks of diagnosis primary tumor; b = early metachronous—within 1 year after diagnosis primary tumor; c = late metachronous—≥1 year after diagnosis primary tumor [32]; ASA = American Society of Anesthesiologists score; TA = thermal ablation—includes microwave ablation (MWA) and radiofrequency ablation (RFA); IRE = irreversible electroporation; SABR = stereotactic body radiation.